Amgen (AMGN) Change in Cash (2009 - 2026)
Amgen (AMGN) recorded quarterly Change in Cash of $2.9 billion in Q1 2026, up 1020.57% quarter-over-quarter from -$316.0 million in Q4 2025, and up 191.97% on a YoY basis from $996.3 million in Q1 2025.
Amgen (AMGN) Change in Cash (2009 - 2026) Analysis & Trends
Amgen's Change in Cash history runs 18 years deep, the most recent figure standing at $2.9 billion for Q1 2026.
- In Q1 2026, Change in Cash rose 191.97% year-over-year to $2.9 billion; the TTM figure through Mar 2026 stood at $3.2 billion (up 459.47% YoY), while the FY2025 annual figure was -$2.8 billion, down 376.38% from the prior year.
- Change in Cash was $2.9 billion for Q1 2026 at Amgen, up from -$316.0 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $23.9 billion in Q1 2023 to a low of -$23.8 billion in Q4 2023.
- Historically, Change in Cash has averaged $238.2 million across 5 years, with a median of -$316.0 million in 2025.
- Biggest YoY gain for Change in Cash was 1737.99% in 2023; the steepest drop was 1170.53% in 2023.
- A 5-year view of Change in Cash shows it stood at -$1.9 billion in 2022, then tumbled by 1170.53% to -$23.8 billion in 2023, then surged by 112.45% to $3.0 billion in 2024, then tumbled by 110.67% to -$316.0 million in 2025, then surged by 1020.57% to $2.9 billion in 2026.
- The last three Change in Cash figures came in at $2.9 billion (Q1 2026), -$316.0 million (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -71.45 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | -1.99 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 1.98 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 4.16 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -9.29 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 65.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 563.00 Mn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -635.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.91 Bn |
| Dec 31, 2025 | -316.00 Mn |
| Sep 30, 2025 | 1.42 Bn |
| Jun 30, 2025 | -782.00 Mn |
| Mar 31, 2025 | -3.16 Bn |
| Dec 31, 2024 | 2.96 Bn |
| Sep 30, 2024 | -290.00 Mn |
| Jun 30, 2024 | -407.00 Mn |
| Mar 31, 2024 | -1.24 Bn |
| Dec 31, 2023 | -23.80 Bn |
| Sep 30, 2023 | 493.00 Mn |
| Jun 30, 2023 | 2.69 Bn |
| Mar 31, 2023 | 23.93 Bn |
| Dec 31, 2022 | -1.87 Bn |
| Sep 30, 2022 | 4.30 Bn |
| Jun 30, 2022 | -1.33 Bn |
| Mar 31, 2022 | -1.46 Bn |
| Dec 31, 2021 | -3.98 Bn |
| Sep 30, 2021 | 5.34 Bn |
| Jun 30, 2021 | 518.00 Mn |